Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Primary central nervous system (CNS) lymphoma \[B-cell, Cluster of Differentiation 20 (CD20) antigen positive\] based on positive biopsy or cerebrospinal fluid (CSF) or vitreous cytology (in association with measurable intraparenchymal tumor). Cytology must demonstrate lymphoma or have an immunohistochemical diagnosis of malignant lymphocytes with a monoclonal lymphocytic population.~2. Life expectancy ≥ 8 weeks;~3. Zubrod performance status of 0-2;~4. Absolute granulocyte count ≥1500/mm3; platelet count ≥ 100,000/mm3; creatinine clearance ≥ 50, calculated with the Cockcroft-Gault Equation: Cr Clearance = (140-age) x wt (kg)/(Cr\[mg/dl\]x 72); Bilirubin, serum glutamate oxaloacetate transaminase (SGOT), alkaline phosphatase (AST) ≤ 2 x institutional upper limits of normal;~5. Patients must sign a study-specific informed consent prior to study entry.~6. Age ≥ 18~Exclusion criteria:~1. Evidence of systemic lymphoma;~2. Prior malignancy (excluding in situ carcinoma of the cervix or non-melanomatous skin cancer)unless disease free for at least five years;~3. Prior radiotherapy to the brain or head/neck;~4. Prior chemotherapy;~5. History of idiopathic sensitivity to any of the drugs to be used;~6. Active infectious process;~7. Seropositive for HIV, AIDS, or post-organ transplant;~8. Pregnant women are ineligible as treatment involves unforeseeable risks to the participant and to the embryo or fetus.~9. Active hepatitis B.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I: Temozolomide 100 mg (Type: EXPERIMENTAL): Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
- Phase I: Temozolomide 150 mg (Type: EXPERIMENTAL): Rituximab, methotrexate, temozolomide 150 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
- Phase I: Temozolomide 200 mg (Type: EXPERIMENTAL): Rituximab, methotrexate, temozolomide 200 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.
- Phase II: Temozolomide 100 mg (Type: EXPERIMENTAL): Rituximab, methotrexate, temozolomide 100 mg/m\^2, followed by radiation therapy, then post-radiation therapy temozolomide 200 mg/m\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).